1 / 7

Neoadjuvant Imatinib in DFSP

Neoadjuvant Imatinib in DFSP. a SARC study U Michigan coordinating center. Dermatofibrosarcoma protuberans. Incidence - 1500 cases per year Low-grade fibrohistiocytic tumor Treated with surgery Imatinib is active in DFSP, has been used in advanced cases.

blue
Télécharger la présentation

Neoadjuvant Imatinib in DFSP

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Neoadjuvant Imatinibin DFSP a SARC study U Michigan coordinating center

  2. Dermatofibrosarcoma protuberans • Incidence - 1500 cases per year • Low-grade fibrohistiocytic tumor • Treated with surgery • Imatinib is active in DFSP, has been used in advanced cases

  3. DFSP: histologic response to imatinib

  4. SARC study: pre-operative imatinib in newly diagnosed DFSP Objectives: • Determine effects of imatinib on phosphorylation of PDGFRB in DFSP • Correlate inhibition of PDGFRB with: • plasma and tissue levels of imatinib • Inhibition of downstream kinases • Inhibition of tumor proliferation – Ki-67/MIB-1 • Induction of apoptosis • Bank patient matched tissue for future study

  5. DFSP: pre-operativetreatment plan • Biopsy to establish diagnosis, obtain pre-imatinib fresh tumor for molecular studies • Imatinib 400 mg bid for 10 to 14 days prior to planned surgical resection • Blood draw for imatinib plasma level within 24 hrs of surgery • Collect tumor for study at surgery • 15 evaluable patients (viable matched tumor tissue/subject taking imatinib)

  6. DFSP: logistics • Pre-imatinib fresh/frozen tumor required • Imatinib-treated fresh/frozen tumor required • CBC at day 7-10 required (safety) • Blood sample for imatinib level at time of surgery required • Gleevec supplied by SARC • Paper case report forms • SARC pay for pre-treatment biopsy

  7. Implementation timeline • Activated at UM October 2005 • Undergoing review at MD Anderson, University of Washington, Memorial, Dana-Farber

More Related